ONCOSEC MEDICAL INC Press Releases

ONCS 
$0.36
*  
-0.005
-1.37 %
Get ONCS Alerts
*Delayed - data as of Jan. 30, 2015  -  Find a broker to begin trading ONCS now


Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By
Vista Partners Initiates Coverage on OncoSec Medical (Ticker: ONCS); Price Target $1.20
1/13/2015 9:00:00 AM - Market Wire


OncoSec Medical Obtains Allowance of Key Patent Application for Intratumoral Delivery of Plasmid IL-15
1/13/2015 6:02:00 AM - Business Wire


OncoSec Medical Obtains Allowance of Key Patent Application for Intratumoral Delivery of Plasmid IL-15
1/13/2015 6:02:00 AM - Business Wire


OncoSec Medical Plans to Initiate Pilot Study in Triple Negative Breast Cancer
1/12/2015 6:02:00 AM - Business Wire


OncoSec Medical to Present at Three Events in January
1/7/2015 6:02:00 AM - Business Wire


OncoSec Medical Announces New Phase II Trial in Head and Neck Cancer Using ImmunoPulse
12/9/2014 6:02:00 AM - Business Wire


OncoSec Medical Announces First Quarter Results for Fiscal Year End 2015
12/8/2014 6:02:00 AM - Business Wire


OncoSec Reports Positive Top-Line Six-Month Primary Endpoint Data from Phase II Melanoma Trial of ImmunoPulse Monotherapy
12/5/2014 11:40:00 AM - Business Wire


OncoSec Medical to Host Corporate Update Conference Call on December 9, 2014
12/5/2014 6:02:00 AM - Business Wire


OncoSec Reports ImmunoPulse May Prolong Survival Based on Analysis of Long-Term Survival Data from Phase I Study in Melanoma
12/4/2014 12:00:00 PM - Business Wire


OncoSec Medical Collaborates with PerkinElmer and University of California, Los Angeles to Evaluate Patient-Selection Biomarker in Immunotherapy
12/2/2014 6:02:00 AM - Business Wire


OncoSec Medical to Present at Two Events in December
11/28/2014 6:02:00 AM - Business Wire


Nature Publication Co-Authored by Robert H. Pierce, Chief Scientific Officer, OncoSec Medical
11/26/2014 1:43:00 PM - Business Wire


UC San Francisco and OncoSec Medical Collaborate to Evaluate Investigational Combination of ImmunoPulse and Anti-PD-1 Treatment
11/25/2014 3:01:00 AM - Business Wire


OncoSec Medical and the University of Washington Enter Sponsored Research Agreement
11/20/2014 6:02:00 AM - Business Wire


OncoSec Medical and Plexxikon Collaborate to Explore Combination Immunotherapy in Preclinical Tumor Studies
11/18/2014 6:03:00 AM - Business Wire


OncoSec Medical To Present at 2014 Stifel Healthcare Conference
11/13/2014 6:02:00 AM - Business Wire


OncoSec Medical Receives VBHRC Funding to Study Novel Gene Therapy Approach in Melanoma
11/10/2014 6:02:00 AM - Business Wire


OncoSec Medical to Present New Clinical Data at Melanoma Bridge 2014
11/5/2014 6:02:00 AM - Business Wire


OncoSec Medical To Present at Three Events in November
11/3/2014 6:02:00 AM - Business Wire